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Non Melanoma Skin Cancer and Subsequent Cancer Risk
Judy R. Rees1,2*, M. Scot Zens1, Jiang Gui1, Maria O. Celaya1,2, Bruce L. Riddle1,2, Margaret R. Karagas1
1 Geisel School of Medicine at Dartmouth, Department of Community and Family Medicine, Biostatistics and Epidemiology Section, Lebanon, New Hampshire, United
States of America, 2 New Hampshire State Cancer Registry, Hanover, New Hampshire, United States of America

Abstract
Introduction: Several studies have shown an increased risk of cancer after non melanoma skin cancers (NMSC) but the
individual risk factors underlying this risk have not been elucidated, especially in relation to sun exposure and skin
sensitivity to sunlight.
Purpose: The aim of this study was to examine the individual risk factors associated with the development of subsequent
cancers after non melanoma skin cancer.
Methods: Participants in the population-based New Hampshire Skin Cancer Study provided detailed risk factor data, and
subsequent cancers were identified via linkage with the state cancer registry. Deaths were identified via state and national
death records. A Cox proportional hazard model was used to estimate risk of subsequent malignancies in NMSC patients
versus controls and to assess the potential confounding effects of multiple risk factors on this risk.
Results: Among 3584 participants, risk of a subsequent cancer (other than NMSC) was higher after basal cell carcinoma
(BCC) (adjusted HR 1.40 [95% CI 1.15, 1.71]) than squamous cell carcinoma (SCC) (adjusted HR 1.18 [95% CI 0.95, 1.46])
compared to controls (adjusted for age, sex and current cigarette smoking). After SCC, risk was higher among those
diagnosed before age 60 (HR 1.96 [95% CI 1.24, 3.12]). An over 3-fold risk of melanoma after SCC (HR 3.62; 95% CI 1.85, 7.11)
and BCC (HR 3.28; 95% CI 1.66, 6.51) was observed, even after further adjustment for sun exposure-related factors and family
history of skin cancer. In men, prostate cancer incidence was higher after BCC compared to controls (HR 1.64; 95% CI 1.10,
2.46).
Conclusions: Our population-based study indicates an increased cancer risk after NMSC that cannot be fully explained by
known cancer risk factors.
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defined population base, but they generally lack detailed individual
cancer risk factor data such as family history of cancer and dietary
information. To our knowledge, few published reports have
combined histological confirmation of NMSC, tumor registry
verification of subsequent cancers, and the analysis of individual
risk factor data [8,9,24,30].
By virtue of their high frequency and low mortality, non
melanoma skin cancers offer an excellent opportunity to study the
factors that put some individuals at increased risk of multiple
malignancies. We had the opportunity to elucidate the risk of
multiple malignancies using a large population-based series of
SCC and BCC cases and controls with individual risk factors
collected through a detailed personal interview. In addition, we
aimed to assess whether the excess risk of cancer after NMSC
could be explained by known cancer risk factors.

Introduction
The non melanoma skin cancers (NMSC) are the most
frequently diagnosed malignancies in the United States [1] with
an estimated 900,000 to 1,200,000 new cases diagnosed each year.
The two major types of NMSC, basal cell (BCC) and squamous
cell carcinoma (SCC), have a relatively small impact on mortality
but their public health impact is considerable. Dramatic increases
in incidence have been documented in recent decades [2–4]. In
New Hampshire, increases of 235% (males) and 350% (females) in
SCC incidence and 80% in BCC incidence were documented
among both males and females over 14 years [4].
Several studies have reported that individuals diagnosed with
non melanoma skin cancers have higher subsequent or prior
diagnoses of second primary malignancies by about 20–60%. [5–
29] Record linkage studies have the advantage of a large, well-
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cancer-related deaths and their dates. The NHSCR database is
checked annually for data quality and consistency using nationally
accepted automated validation tools, and the database from 2000
onwards is estimated to be over 99% complete, according to
formulae applied by the National Program for Cancer Registries
(NPCR). These NPCR evaluations began in 1995; between 1995
and 1999, NHSCR completeness estimates ranged between 88%
and 95%.

Materials and Methods
Ethics Statement
The New Hampshire Skin Cancer Study (NHSCS) and the
additional work described here were approved by the Committee
for the Protection of Human Subjects of Dartmouth College.
Participants in the NHSCS underwent a written, informed consent
process at enrollment. Use of data from the New Hampshire State
Cancer Registry was approved by the New Hampshire Department of Public Health Services. Confidentiality was also protected
by use of a de-identified dataset in the statistical analyses.

Exclusions of Individuals with a Prior History of Cancer
We excluded from the main analyses any individual with a prior
history of cancer other than skin cancer (NMSC and melanoma).
This exclusion encompassed any non-skin cancer diagnosed before
the reference date identified either through NHSCR records or via
self-report at the study enrollment interview. Self-reports of major
cancers have previously been shown to be fairly reliable [33,34]
and allowed us to identify cancers that would not have been
ascertained by our registry (i.e., occurred outside New Hampshire
or before 1995). For consistency between self-reported and
NHSCR cancers, registry-reported in situ malignancies (excluding
cervix and prostate) were included among ‘‘prior’’ cancers.

New Hampshire Skin Cancer Study
The New Hampshire Skin Cancer Study (NHSCS) was first
conducted as a population-based case-control study of non
melanoma skin cancers (NMSC) diagnosed between July 1, 1993
and June 30, 2002 (New Hampshire residents), obtained through
intensive surveillance at dermatologists’ offices and pathology
laboratories serving the state. Case selection criteria earlier in the
study tended to oversample patients with SCC relative to their
incidence in the population, and in later years there was
oversampling of cases diagnosed before the age of 51 years
(‘‘early-onset’’), or with multiple concomitant BCCs. Cases with
both incident BCC or SCC during the enrollment phase were
eligible based on either diagnosis, as dictated by the sampling
methods of the parent study. Controls were selected from NH
residents provided by the NH Department of Transportation,
frequency matched on age and sex. [31] Although the skin cancer
study includes individuals with all ethnic backgrounds, they were
recruited from the New Hampshire population which was ,98%
white (1990 US Census). The date of diagnosis, or a matched
comparable date generated for controls, served as the reference
date for this study. Collection of the data occurred in several
phases, with the addition of new variables as the study progressed.
Detailed risk factor information was obtained from personal
interviews on 2,713 individuals with NMSC (SCC 1,170; BCC
1,543), and 1,416 age- and sex-matched controls. This included
information about smoking, education, skin type, lifetime sun
exposure habits including number of painful sunburns, skin type,
number of nevi, body mass index, weight gain since age 18,
smoking, alcohol consumption, nutritional information including
dietary and supplementary intake of vitamin D, folic acid, and
multivitamins, history of cancer, radiotherapy, prescription and
over the counter drug use, and family history of cancer including
age at diagnosis and cancer site. Toenail arsenic was also
measured and analyzed using instrumental neutron activation
analysis. For the purposes of the analyses described here, the
original groups (BCC, SCC and controls) were followed as a
retrospective cohort.

Ascertainment of Cancer Following NMSC
To identify cancers that were diagnosed after the reference date,
we linked the NHSCS database with the NHSCR incident cancers
database for diagnosis through 2009, which, on July 23rd, 2010,
contained 149,523 individuals. We used LinkPlus software [35] to
conduct probabilistic matching based on social security number,
last name, first name, date of birth and sex. The software listed the
linked records in order of the estimated probability of a true match
and one author (JR) manually reviewed linkage variables alongside
street address, zip code and telephone number as additional means
of linkage verification. Because the definitions of reportable
cancers changed over time, we based our definition of subsequent
cancers on those reportable in 2008 [36]. Subsequent cancers were
defined as cancers reported to the NHSCR with stage 1 or higher
(invasive disease), or any bladder cancers (including in situ, stage
0); data on malignant melanomas were collected, but melanomas
were examined separately in some analyses.

Identification of Deaths
We linked both the NHSCR and NMSC databases with the
New Hampshire death certificate database to identify deaths from
1993 through 2009. We again used LinkPlus combined with
manual review to determine deaths among study participants. In
addition, we linked with the National Death Index (NDI) through
2009 to identify deaths nationwide. Death data were used to
provide censor dates in the survival analysis, and to identify
potential cancers that were not identified from cancer registry
data.

New Hampshire State Cancer Registry
The New Hampshire State Cancer Registry (NHSCR) is a
population-based database of incident, reportable cancers containing, on average, ,6,500 verified new cases annually among
the New Hampshire population of 1.2 million. Incidence data for
1995 onwards meet the standards of the North American
Association of Central Cancer Registries for quality and
completeness [32]. Case ascertainment from 1986 through 1995
is partially complete, and some information on non-reportable
cases (diagnosed before 1986 or before the patient took up
residence in New Hampshire) is held by NHSCR in separate
databases. The New Hampshire State Cancer Registry annually
links its database with the National Death Index and with death
certificate files from the state of New Hampshire, to identify
PLOS ONE | www.plosone.org

Statistical Analysis
Although the parent study was a case control design, the data
were analyzed for this study in a cohort design, using follow-up
information from the date of enrollment for participants with BCC
or SCC, and controls. The endpoint of our analysis was the time
from the reference date to diagnosis of first cancer. Participants
who did not develop cancer were censored on the date of death or
at the end of follow-up (December 31, 2009), whichever came first.
We used Cox models to determine the hazard ratios (HRs) and
95% confidence intervals (CI) associated with development of a
subsequent cancer for BCC and SCC cases (separately) versus
controls. We also performed stratified analyses by sex and by age
2
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group (,60 or $60 years) and restricted to invasive cancers. For
all analyses, the HRs were adjusted for known the cancer risk
factors, age, sex, and smoking status (never, former, current). We
plotted the survival curves in the BCC, SCC and control groups to
check the proportional hazards assumption and separately assessed
the hazard functions. We examined the contribution of additional
variables to the model (e.g., sun exposure, body mass index) by
assessing the change in the primary measure of effect; thus, we
included variables in the age-, sex-, smoking-adjusted model which
led to a 10% or greater change in the hazard ratio for BCC, SCC
or NMSC (BCC and SCC combined). [37] We further developed
models for site-specific analyses, in which we redefined the end
point as diagnosis of the specific cancer (e.g. time to first
melanoma, time to first prostate cancer) whether or not there
were intervening cancers of a different kind. We conducted
sensitivity analyses (i) after excluding subsequent cancers diagnosed within the first year after the referent NMSC, (ii) after
excluding individuals with a prior melanoma; (iii) defining prior
cancers only by self report; and (iv) defining prior cancers only via
the registry. We also separately assessed the risk of subsequent
cancer in those who had been excluded from the primary analysis
because of a prior cancer (File S1).

cigarette smoking (HR 1.53; 95% 1.21, 1.94, Table S1 in File S1).
Occupational sun exposure was associated with a statistically
significantly lower risk of cancer after BCC (e.g. highest vs. lowest
quartile HR 0.72 (95% CI 0.53, 0.97), but was not retained in the
model as it did not impact the association between BCC and
subsequent cancer. Other factors that appeared to be unrelated to
risk of subsequent cancer included education, BMI, weight gain
since age 18, skin reaction to chronic sun exposure, lifetime warm
month sun exposure, family history of cancer, folate intake, and
toenail arsenic concentration and skin reaction to acute sun
exposure, lifetime painful sunburns, self reported number of nevi
on the back, BMI at age 18, vitamin D intake; warm month
cumulative sun exposures as adult and as child; proportion of sun
exposure that was recreational; history of radiotherapy; regular use
of oral steroids, aspirin, acetaminophen, non-steroidal antiinflammatory agents; age first started smoking; coffee, tea or
alcohol consumption; family history of cancers of all major sites
(each of which was tested separately if female, male, age ,50, age
.50) (data not shown). We further examined risks of subsequent
melanoma and other specific types of cancers following NMSCs
(Table 3). Risk of both melanoma and prostate cancers were
higher after NMSC compared with controls. In an analysis of time
to diagnosis of melanoma, we found a 3-fold increase in risk after
BCC (HR 3.28; 95% CI 1.66, 6.51), after adjustment for age, sex
and smoking, skin reaction to chronic sun exposure and family
history of non melanoma skin cancer. The hazard ratio for SCC
versus controls (HR 3.62; 95% CI 1.85, 7.11) adjusted for age, sex,
smoking, skin reaction to chronic sun exposure was likewise
elevated. Family history of NMSC was unrelated to cancer risk
following an SCC and therefore not included as a covariate this
model. For all NMSC combined, a family history of NMSC was
associated with an increased risk of subsequent melanoma (HR
1.60; 95% CI 1.01, 2.52). Following BCC, a lower risk of
subsequent melanoma was seen in former smokers when
compared to never smokers (HR 0.49; 95% CI 0.26, 0.91; Table
S1 in File S1). A similar pattern was seen after SCC, but without
statistical significance. Excluding melanomas diagnosed within 12
months of the referent NMSC did not diminish the hazard
associated with NMSC status (data not shown). The hazard ratios
for melanoma after BCC were higher among older patients $60
years (HR 5.24; 95% CI 1.96, 14.01) than younger ones (HR 1.76;
95% CI 0.67, 4.61). A similar pattern was seen in SCC (Table 3).
After excluding melanoma, the hazard ratios reflecting cancer risk
after BCC and SCC were lower, but still statistically significantly
increased among men after BCC and among those aged ,60 at
the time of diagnosis of SCC (Table 3).
An increased risk of prostate cancer was observed after BCC
(HR 1.64; 95% CI 1.10, 2.46) but not SCC adjusted for age, sex
and smoking. These hazard ratios were not appreciably altered by
other risk factors, nor by exclusion of prostate cancers diagnosed
within 12 months of the referent lesion (data not shown). We
examined risk of subsequent cancers in several subgroups. For
individuals with multiple BCC (defined as two or more tumors
within 30 days), the adjusted HR for all subsequent cancers
(including in situ) relative to all controls was 1.59 (95% CI 1.11,
2.27), and 1.39 (0.93, 2.08) for only invasive subsequent cancers.
When an individual’s referent BCC occurred before age 50, the
adjusted HR was similar to that seen in the primary analysis (HR
1.40; 95% CI 0.79, 2.49) for all subsequent cancers but lower (HR
1.09; 95% CI 0.59, 2.01) for invasive subsequent cancers.
Overall, approximately 1% of NMSC patients were found to
have another malignancy within a year of their diagnosis. During
the first year of observation, an internal cancer or melanoma was

Results
The skin cancer study provided interview data from a total of
4,223 individuals followed for a mean of 10.9 years (range 0.8 to
17.0). From the 1,600 individuals enrolled as a result of a diagnosis
with BCC, 1,125 with SCC and 1,498 controls (Table 1), we
excluded 642 participants with prior internal cancers based on selfreport or registry confirmation from the analysis. These exclusions
represented 10.5% of those without a history of NMSC, 14.8% of
those with a history of BCC and 22.0% with SCC.
The mean age of the remaining 3,584 participants included in
the analysis was 57.5 (standard deviation 11.7), and 55% were
male. During follow-up, 562/3584 (15.7%) eligible participants
died from any cause; 203/1,341 (15.1%) of controls, 170/1,363
(12.5%) of those with BCC and 189/880 (21.6%) with SCC. A
total of 560 individuals (13.7%) developed 646 subsequent cancers
during follow-up; 485 developed 1 type of cancer; 65 developed 2
types of cancer; 10 developed 3 or more types of cancer.
After adjusting for age, sex and smoking (never, former,
current), the risk of a subsequent cancer (excluding NMSC) was
higher following a BCC diagnosis compared to controls (HR 1.40
[95% CI 1.15, 1.71]). The hazard ratios for BCC were
significantly elevated among men (HR 1.55 [95% CI 1.21,
1.99]) but not women (HR 1.14 [0.81, 1.60]) and among
participants aged 60 or more at enrolment (HR 1.43 [95% CI
1.14, 1.80]) but not among those younger than 60 years (HR 1.31
[95% CI 0.88, 1.95]). Following SCC, we observed a more
modest, not statistically significant increase overall (HR 1.18 [95%
CI 0.95, 1.46]). However, the risk of subsequent cancer after SCC
was substantially increased when diagnosed before age 60 (HR
1.96 [95% CI 1.24, 3.12]), whereas no effect was seen among
those diagnosed at age 60 or older (HR 1.00 [95% CI 0.79, 1.28])
and this difference was statistically significant (p,0.003). In
contrast, significant interactions were not seen between age group
and BCC, nor between sex and either BCC or SCC (Table 2). The
proportional hazards assumption was supported by review of
survival plots and hazard functions for the three groups (BCC,
SCC and control).
Factors other than a history of NMSC that were related to risk
of subsequent cancer included increasing age (HR 1.06; 95% CI
1.05, 1.07), male sex (HR 1.44; 95% 1.21, 1.73) and current
PLOS ONE | www.plosone.org
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8 (6.0%)
19 (14.2%)

Unstaged

Unknown

4 (6.0%)

3 (4.5%)

2 (3.0%)

58 (86.6%)

22 (10.9%)

10 (5.0%)

158 (78.6%)

11 (5.5%)

201

186

11.0

1,341 (89.5%)

157 (10.5%)

1,498

11 (6.3%)

13 (7.4%)

136 (77.7%)

15 (8.6%)

175

140

11.3

683 (84.0%)

130 (16.0%)

813

5 (6.0%)

6 (7.1%)

55 (65.5%)

18 (21.4%)

84

73

11.1

680 (86.4%)

107 (13.6%)

787

Women

16 (6.2%)

19 (7.3%)

191 (73.7%)

33 (12.7%)

259

213

11.2

1,363 (85.2%)

237 (14.8%)

1,600

All

12 (9.2%)

9 (6.9%)

96 (73.8%)

13 (10.0%)

130

110

10.1

540 (77.1%)

160 (22.9%)

700

Men

SCC1

4 (7.1%)

3 (5.4%)

40 (71.4%)

9 (16.1%)

56

51

10.7

337 (79.3%)

88 (20.7%)

425

Women

16 (8.6%)

12 (6.5%)

136 (73.1%)

22 (11.8%)

186

161

10.4

877 (78.0%)

248 (22.0%)

1,125

All

2

Of 2,725 cases, 82 (3%) had both a BCC and SCC diagnosed within 30 days of the reference date. Of these, oversampling for SCC cases led 79 to an SCC classification.
Participants with cancer of any organ except the skin, diagnosed before the reference date, were excluded from the main analyses. Relative to controls, the odds ratio for a history of non-skin cancer in those with BCC was,
adjusted for age, sex and smoking: odds ratio 1.74 (95% CI 1.40, 2.18) and for SCC, OR 1.99 (95% CI 1.59, 2.89).
3
Total exceeds number of participants with subsequent cancer because a participant may be diagnosed with multiple primary tumors.
doi:10.1371/journal.pone.0099674.t001

1

7 (5.2%)
100 (74.6%)

Stage of tumors3

Invasive (stage 1–4, stage 0 bladder)

67

134

Tumors diagnosed after
reference date3

In situ (stage 0 except bladder)

65

121

Participants with cancer diagnosed after
reference date

11.1

581 (87.4%)

760 (91.2%)
10.9

84 (12.6%)

665

Mean years of follow-up per person

73 (8.8%)

833

Excluded due to prior non skin cancer2

Included in the analyses

Participants in the study

Men

All

Men

Women

BCC1

Controls

Table 1. Follow-up of participants and their subsequent cancers after non melanoma skin cancer.
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131
1.43 (1.14, 1.80)3
149
$60 years old

51

59
1.14 (0.81, 1.60)

,60 years old

1.31 (0.88, 1.95)3

73

64

Women

123

3

1.55 (1.21, 1.99)3
140
Men

182
213
All participants

1.40 (1.15, 1.71)

PLOS ONE | www.plosone.org

Hazard ratios are based on time to subsequent cancer compared to controls, adjusted for age at reference date, sex and smoking; stratified models are similarly adjusted except for the stratification variable. Where shown in bold,
HR is statistically significant (alpha = 0.05).
1
All cancers: invasive plus in situ cancers of sites other than cervix and prostate.
2
Invasive cancers: stage 1–4 cancers and stage 0 bladder.
3
The HR associated with BCC did not vary significantly by sex or by age group.
4
The HR associated with SCC did not vary significantly by sex, but was significantly higher in those aged ,60 than those aged $60 (p,0.003).
doi:10.1371/journal.pone.0099674.t002

1.64 (0.98, 2.72)

1.06 (0.70, 1.61)

0.96 (0.74, 1.25)
101
1.00 (0.79, 1.28)4
122
1.45 (1.13, 1.85)

30

1.12 (0.84, 1.49)
91

40
1.22 (0.84, 1.79)

1.96 (1.24, 3.12)4
39

51
1.02 (0.70, 1.47)

1.16 (0.75, 1.78)

4

1.17 (0.90, 1.52)4
110
1.60 (1.23, 2.09)

HR (95% CI)

1.09 (0.86, 1.38)
131
1.18 (0.95, 1.46)
161
1.37 (1.11, 1.70)

Number with
invasive cancer
Number with
invasive cancer
HR (95% CI)
Number with
cancer

All cancers

1

Invasive cancers

2

HR (95% CI)

Number with
cancer

HR (95% CI)

Invasive cancers2
N = 880
N = 1,363

All cancers1

SCC
BCC

Table 2. Hazard ratios (95% confidence intervals) for subsequent cancers (all, and invasive cancers only) following basal cell and squamous cell skin cancers compared to controls.
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diagnosed in 12/880 (1.4%) SCC patients, 9/1363 (0.7%) BCC
patients, and only 1/1341 (,0.1%) controls (data not shown).
In sensitivity analyses, we obtained similar results after: (i)
excluding cancers diagnosed within the first year, (ii) excluding
individuals from the analysis who had a prior melanoma (as well as
other non skin cancer); (iii) defining prior cancers by self report
only or (iv) by registry report only (File S1).

Discussion
In our study, we identified a significantly increased cancer risk
after BCC that could not be explained by a variety of
environmental, nutritional or behavioral risk factors or by family
history of cancer. The increased cancer risk after SCC appeared to
be largely confined to those with SCC diagnosed before the age of
60. In our population, the strongest association was for subsequent
melanoma of the skin, supporting common susceptibility and
exposures such as ultraviolet light in the etiology of skin
malignancies. However, after excluding melanoma, there remained a statistically significant increased risk of subsequent
malignancy after BCC, especially among men. Any attempt to
explain the increased cancer risks after NMSC must consider the
environmental, genetic, and personal characteristics that could
predispose to both NMSC and other cancers. By adding important
explanatory factors to the models, we would expect to see a
reduction in the adjusted hazard ratios for risk of cancer after
NMSC, but NMSC-related hazard remained in our study, despite
the inclusion of many potential risk factors. This suggests the need
for studies of more detailed risk factor data including genetic
analyses in large populations. [38,39].
A few other published studies have incorporated histological
confirmation of NMSC, cancer registry confirmation of subsequent cancer, and multivariable adjustment for individual risk
factors. The largest of these was based on 36,102 individuals with
NMSC from US prospective cohorts followed by Song et al
through postal questionnaires that collected individual level risk
factors, although estimates of cumulative sun exposure or family
history of NMSC were not available. [24] In multivariable
analyses, they found that SCC was associated with a 24% increase
in risk in women but little to no association in men; BCC was
associated with a 25% increase in risk in women and 17% in men.
The increased risk after NMSC in that study was seen among
never and former smokers but not among current smokers, which
raises questions about heterogeneity in the mechanism of
carcinogenesis. That is, an individual with SCC that arose
primarily due to smoking may have a different causal pathway
to subsequent cancer than an individual with SCC that arose
through other mechanisms, such as an intrinsic susceptibility to
cancer. Song et al also detected no substantial differences in the
association between NMSC and subsequent cancer by ultraviolet
light (UVL) exposure at their place of residence, BMI or age. In
contrast, we found associations between NMSC and subsequent
cancer in those aged ,60 (but not in those $60) at diagnosis of
SCC, and among those aged $60 (but not in those ,60) at
diagnosis of BCC. Others have also found higher risks of
subsequent cancer after NMSC in younger age groups. [13,21]
Studies of Kaiser Permanente patients reported estimates of
relative risk closer to ours, based on 822 patients with in situ or
invasive SCC (HR 1.4; 95% CI 1.2, 1.6) [8], and on 3164 patients
with BCC (HR 1.2; 95% CI 1.1, 1.4) [9]. Chen studied 165
individuals with SCC, 513 with BCC, 60 with both and 31 with
unknown subtype from the volunteer-based CLUE II cohort. A
higher relative risk of cancer associated with prior NMSC (HR
1.99; 95% CI 1.70, 2.33) was observed than in our population5

June 2014 | Volume 9 | Issue 6 | e99674

Malignancy after Non Melanoma Skin Cancer

Table 3. Site-specific cancers risk after basal cell and squamous cell skin cancers versus controls.

Controls

Cancer site

All cancers

All cancers except
melanoma

Melanoma

BCC vs controls

SCC vs controls

N = 1341

N = 1,363

N = 880

Number with
cancer

Number with
cancer

HR (95% CI)

Number with
cancer

HR (95% CI)

All

186

213

1.40 (1.15, 1.71)

161

1.18 (0.95, 1.46)

Men only

121

140

1.55 (1.21, 1.99)

110

1.17 (0.90,1.52)

Women only

65

73

1.14 (0.81, 1.60)

51

1.22 (0.84, 1.79)

,60 y

40

64

1.31 (0.88, 1.95)

39

1.96 (1.24, 3.12)

$60 y

146

149

1.43 (1.14, 1.80)

122

1.00 (0.79, 1.28)

All

177

180

1.24 (1.01, 1.54)

136

1.01 (0.81, 1.27)

Men only

115

117

1.37 (1.05, 1.78)

91

0.98 (0.74, 1.30)

Women only

62

63

1.03 (0.72, 1.48)

45

1.11 (0.74, 1.30)

,60 y

35

50

1.17 (0.76, 1.82)

29

1.67 (0.99, 2.81)

$60 y

142

130

1.27 (1.00, 1.61)

107

0.89 (0.69, 1.15)

All

15

63

3.28 (1.66, 6.51)1

42

3.62 (1.85. 7.11)2
3.53 (1.63, 7.62)

Men only

12

46

3.19 (1.48, 6.91)

32

Women only

3

17

3.87 (0.82, 18.22)

10

4.29 (1.05, 17.53)

,60 y

7

30

1.76 (0.67, 4.61)

11

2.15 (0.76, 6.10)

$60 y

8

33

5.24 (1.96, 14.01)

31

4.32 (1.75, 10.67)

All

42

56

1.64 (1.10, 2.46)

32

0.93 (0.59, 1.49)

,60 y

5

15

2.49 (0.90, 6.88)

5

1.58 (0.44, 5.59)

$60 y

37

41

1.51 (0.97, 2.36)

27

0.84 (0.51, 1.39)

Lung

33

27

1.14 (0.68, 1.90)

16

0.69 (0.38, 1.25)

Female breast

20

24

1.13 (0.62, 2.06)

16

1.24 (0.63, 2.45)

Colorectal

24

19

0.92 (0.50, 1.69)

17

0.82 (0.43, 1.56)

Bladder

11

13

1.47 (0.65, 3.31)

9

1.02 (0.42, 2.48)

Non Hodgkin lymphoma

7

6

1.08 (0.36, 3.26)

9

1.59 (0.59, 4.31)

Uterus

11

5

0.42 (0.15, 1.23)

4

0.63 (0.19, 2.07)

Prostate

Hazard ratios refer to NMSC status (vs controls), adjusted for age at reference date, sex and smoking.
The melanoma models for BCC are adjusted for age at reference date, sex, smoking, skin reaction to chronic sun exposure and family history of NMSC.
2
The melanoma models for SCC are adjusted for age at reference date, sex, smoking, skin reaction to chronic sun exposure.
Stratified models are similarly adjusted except for the stratification variable.
doi:10.1371/journal.pone.0099674.t003
1

concern in New Hampshire, we did not find an association
between toenail arsenic concentration and overall cancer risk, nor
any impact in our models. [42].
While our study did not indicate that sun exposure affected non
skin cancer risk, it is possible that the sample size may have been
too small to do so, especially for specific types of cancers.
However, we did detect an excess risk of melanoma following both
BCC and SCC with significantly increased melanoma risk in
participants reporting a family history of NMSC, but not a family
history of melanoma which is a known risk factor for melanoma.
[43] Melanoma risk was also increased among individuals who
peel or develop moderate tans upon chronic sun exposure
(compared to those who develop a deep tan). Former smokers
had a significantly lower risk of melanoma after NMSC and a risk
reduction was seen in current smokers but this could have been
due to chance; several other studies have reported reduced
melanoma risk in smokers, but no adequate explanation for this
has been put forward except for the possibility of bias caused by
competing risk due to unknown confounders. [44] Family history
of melanoma did not contribute significantly to the model as in

based study [30]. None of these studies, including our own, could
explain away all of the NMSC-related risk in terms of individual
risk factor data.
Other than NMSC, cancers related to UVL exposure, or
suspected to be so, include malignant melanoma, cancer of the lip,
non-Hodgkin’s lymphoma and leukemias; these are among the
cancers that appear to be more common after NMSC in prior
studies [11,15,18–20,25–27,40,41]. When assessing all subsequent
cancers together, we did not find any significant changes in risk
associated with skin type, number of lifetime painful sunburns, or
the number of hours spent outdoors during warm months, nor any
modification of the increased risk associated with NMSC. The
amount of time spent outdoors in an occupational setting was
associated with a lower risk of subsequent cancer, after adjustment
for age, sex and smoking, but, given the lack predictive value of
other sun exposure measures, it seems likely that this may
represent confounding by other lifestyle factors. The increased
risks observed also persisted after accounting for family history of
cancer, including having a first degree relative diagnosed with
cancer before age 50. Although arsenic in well water is a known
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Another limitation is that we were unable to assess the impact of
race because the study population based in New Hampshire lacks
racial diversity. Previously, a large cross-sectional study found that
self-reported NMSC was more likely to be associated with other
self-reported cancers in black than white women [23]. However, it
is unclear how much of this apparent effect modification by race
reflects a stronger association between NMSC and subsequent
cancer in black women or simply differences in patterns of selfreporting of cancers [23]. The ascertainment of cancers before
1995 is a limitation of our study, because cancer registry data
before 1995 were less complete. In addition, cancer case
ascertainment by the NH State Cancer Registry depended on
continued residence in New Hampshire or another state (including
its immediate neighbors) that reports to New Hampshire.
Sensitivity analyses using different definitions of prior cancer,
including self-report, confirmed our major findings (data not
shown). Finally, our results include the results of many comparisons; as we did not statistically address the impact of multiple
testing, it is possible that some of our findings may be the result of
chance.
In summary, individuals with NMSC and no prior history of
non-skin cancer were more likely to develop another cancer
following a NMSC diagnosis, particularly melanomas. Detailed
individual risk factors other than age, sex and smoking could not
explain this increase in cancer risk overall. Sun sensitive skin type
and family history of NMSC explained a small fraction of the
excess melanoma risk after NMSC, but adjustment for several
other known and putative cancer risk factors did not remove the
association between NMSC and subsequent melanoma or other
cancers. Understanding the shared risk factors that contribute to
multiple malignancies may lead to new etiologic insights. In
particular, larger studies incorporating detailed genetic data may
help to identify NMSC patients at greatest risk for subsequent
cancers and who may benefit from more intensive screening.

other studies, [45] but the numbers with such a history in our
cohort were much smaller. We found that the excess risk of
melanoma after BCC or SCC remained after accounting for
known risk factors such as sun sensitive skin type. On balance, our
findings raise the possibility of unmeasured or unknown shared
genetic risk factors for melanoma and BCC.
In the site-specific analysis, we further found that BCC but not
SCC was associated with an increased risk of subsequent prostate
cancer. Again, we did not identify any additional risk factors that
affect our risk estimates, or could explain this association.
However, our approach was potentially limited by lack of
statistical power and our method of including site-specific cancers
even if intervening cancers occurred. For example, if a BCC were
followed by a breast cancer and then a lung cancer, the lung
cancer would be included in the site-specific analysis despite the
possibility that treatment of the breast cancer may have played a
role in the lung cancer etiology.
Participants with NMSC in this study were selected from a
population-based surveillance program, and are therefore expected to represent reasonably well the general population of
individuals diagnosed with NMSC, although it should be noted
that the relative proportions of SCC and BCC patients in our
study do not reflect population incidence due to oversampling of
SCC patients in the parent study. In particular, 3% of cases were
diagnosed with both a BCC and SCC within a 30-day period, and
these were over-represented in the SCC group. We could not
assess the proportions of patients who were diagnosed with both
cancers during the course of the study or during their lifetime,
although it would have been interesting to analyze this group’s
subsequent risks separately. An additional limitation is that
controls may have subsequently developed NMSC during a
decade of observation, and would therefore be misclassified as
controls; this would tend to bias the results of our study towards
the null, and reduce our ability to identify true associations
between NMSC and the risk of subsequent cancer. Although the
expected frequency of subsequent NMSC among controls is
relatively high because NMSC are common cancers, fewer than
0.1% of controls developed a major cancer during the first year
after the reference date, a figure comparable to the similarly aged
US population [46]. A higher proportion of those with NMSC –
almost 1% - developed another type of cancer during that first
year. While it seems likely that increased medical surveillance after
NMSC might account for this observation, we did not find clear
evidence that earlier cancers were of an earlier stage, and
exclusion of cancers diagnosed within one year did not materially
change our results. Irrespective of whether these findings reflect
detection bias, it may be useful for dermatologists to know that
1.4% of our patients diagnosed with SCC, and 0.7% of those with
BCC had an internal cancer or melanoma that could be diagnosed
within 12 months after an NMSC diagnosis.
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